Skip to main content

Invivoscribe CE-IVD LymphoTrack Dx Assays

Invivoscribe Technologies has launched three new CE-marked in vitro diagnostic assays for the company's Ion PGM Dx System. The new assays include an IGH, IGK, and TRG clonality assays to aid in the diagnosis of B-cell malignancies. When the IGH and IGK assays are used together, it's possible to detect clonality in a majority of B-cell malignancies with nearly 100 percent clinical sensitivity, the company said. Additionally, when all three assays are used together, it is possible to detect a least one clonal biomarker target in the vast majority of hematologic malignancies, the company said.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.